Cayman Chemical Company Incorporated

Corgenix Medical Corporation

Myometrics LLC

Kirk M Maxey

Stephen Douglas Barrett

Gregory William Endres

Adam Uzieblo

Fred Lawrence Ciske

Bradlee David Germain

James Bernard Kramer

Andriy Kornilov

Joseph Michael Colombo

F Jon Geske

Amy Whittier

Daniel Tew

Michelle L Stanton

Thomas Allen Owen

James Paul O'Malley

Andriy Komilov

Nancy Sue Barta

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

Difluorolactam compounds as EPreceptor-selective agonists for use in the treatment of EP-mediated diseases and conditions

Disclosed herein are compounds of formula (I) wherein L, L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

[object Object]

Disclosed herein are compounds of formula (I) wherein L, L, L, R, R, R, and Rare as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.

Methods and kits for detection of thromboxane A2 metabolites

A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.

Prostaglandin E1 and E2 analogs for the treatment of various medical conditions

Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction of ocular hypertension.

Internal 1,15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension

Growing community of inventors

Ann Arbor, MI, United States of America

Kirk M Maxey